These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 14696090)
1. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Pedersen MW; Tkach V; Pedersen N; Berezin V; Poulsen HS Int J Cancer; 2004 Feb; 108(5):643-53. PubMed ID: 14696090 [TBL] [Abstract][Full Text] [Related]
2. EBV-expressing AGS gastric carcinoma cell sublines present increased motility and invasiveness. Kassis J; Maeda A; Teramoto N; Takada K; Wu C; Klein G; Wells A Int J Cancer; 2002 Jun; 99(5):644-51. PubMed ID: 12115496 [TBL] [Abstract][Full Text] [Related]
3. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870 [TBL] [Abstract][Full Text] [Related]
4. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Pedersen MW; Pedersen N; Ottesen LH; Poulsen HS Br J Cancer; 2005 Oct; 93(8):915-23. PubMed ID: 16189524 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460 [TBL] [Abstract][Full Text] [Related]
6. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063 [TBL] [Abstract][Full Text] [Related]
7. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640 [TBL] [Abstract][Full Text] [Related]
8. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Abulrob A; Giuseppin S; Andrade MF; McDermid A; Moreno M; Stanimirovic D Oncogene; 2004 Sep; 23(41):6967-79. PubMed ID: 15273741 [TBL] [Abstract][Full Text] [Related]
9. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Gildea JJ; Harding MA; Seraj MJ; Gulding KM; Theodorescu D Cancer Res; 2002 Feb; 62(4):982-5. PubMed ID: 11861368 [TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
13. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Zhan Y; O'Rourke DM Cancer Res; 2004 Nov; 64(22):8292-8. PubMed ID: 15548697 [TBL] [Abstract][Full Text] [Related]
14. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113 [TBL] [Abstract][Full Text] [Related]
16. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Schmidt-Ullrich RK; Mikkelsen RB; Dent P; Todd DG; Valerie K; Kavanagh BD; Contessa JN; Rorrer WK; Chen PB Oncogene; 1997 Sep; 15(10):1191-7. PubMed ID: 9294612 [TBL] [Abstract][Full Text] [Related]
17. Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Lorimer IA; Lavictoire SJ Biochim Biophys Acta; 2001 Feb; 1538(1):1-9. PubMed ID: 11341977 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Ning Y; Zeineldin R; Liu Y; Rosenberg M; Stack MS; Hudson LG Cancer Res; 2005 Oct; 65(20):9280-6. PubMed ID: 16230389 [TBL] [Abstract][Full Text] [Related]
19. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Li B; Chang CM; Yuan M; McKenna WG; Shu HK Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544 [TBL] [Abstract][Full Text] [Related]
20. Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice. Xian W; Kiguchi K; Imamoto A; Rupp T; Zilberstein A; DiGiovanni J Cell Growth Differ; 1995 Nov; 6(11):1447-55. PubMed ID: 8562483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]